How was extent and severity of skin lesions (EASI) assessed in DUPIXENT atopic dermatitis clinical trials?

The Eczema Area and Severity Index (EASI) combines the severity of eczema signs and the extent of skin involvement to measure lesional signs of AD.⁸

The severity of each of 4 eczema signs is assessed on a scale of 0 to 3⁸

The signs of eczema (erythema, edema/papulation, excoriation, and lichenification) are graded using a defined process by the extent to which the patient is affected

The extent of lesions in each body region is evaluated⁸

The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6
Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least

Each region gets a total region score⁸:

Severity Score x Area Score x Multiplier = Region Score

The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.^8,a

An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is considered a clinically meaningful change.¹

^aIn patients <8 years of age, the multipliers for the head and neck are 0.2, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.3. In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.⁸